<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Fuentes | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/polandskiing57/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/polandskiing57/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Fuentes.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">610ad70742514ff6db86316e68537ffb</guid>
				<title>Fuentes posted an update: L. GG-Cf could treat murine breast cancer, and MINPs are a [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/37737/</link>
				<pubDate>Mon, 03 Feb 2025 12:00:39 -0800</pubDate>

									<content:encoded><![CDATA[<p>L. GG-Cf could treat murine breast cancer, and MINPs are a suitable candidate for drug delivery because of their safety, uniformity, and magnetic properties.</p>
<p>L. GG-Cf could treat murine breast cancer, and MINPs are a suitable candidate for drug delivery because of their safety, uniformity, and magnetic properties.</p>
<p> To explore the regulation&hellip;<span class="activity-read-more" id="activity-read-more-37737"><a href="http://www.nationalboardinstitute.com/activity/p/37737/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e574663ca19fa26c46bd26e251b6e641</guid>
				<title>Fuentes posted an update: BACKGROUND Ivor-Lewis esophagectomy (ILE) is the standard [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/31918/</link>
				<pubDate>Tue, 28 Jan 2025 17:38:48 -0800</pubDate>

									<content:encoded><![CDATA[<p>BACKGROUND Ivor-Lewis esophagectomy (ILE) is the standard surgical care for esophageal cancer patients but postoperative morbidity impairs quality of life and reduces long-term oncological outcome. Two-stage ILE separating the abdominal and thoracic phase into two distinct surgical procedures has proven to enhance microcirculation of the gastric&hellip;<span class="activity-read-more" id="activity-read-more-31918"><a href="http://www.nationalboardinstitute.com/activity/p/31918/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">4db0086dc41759d8c3d5209a27a39857</guid>
				<title>Fuentes became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/31885/</link>
				<pubDate>Tue, 28 Jan 2025 17:36:13 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>